Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-067i
- Development stage
- Preclinical
- Lead developer
- Metsera
- Modality
- Peptides
01
Overview
MET-067i is a synthetic peptide drug candidate developed by Metsera for the treatment of obesity. It acts as an agonist of the glucagon receptor (GCGR), making it part of a class known as glucagon receptor agonists. The drug is being investigated for its potential to induce weight loss through activation of GCGR pathways involved in metabolic regulation. As of May 2025, it remains in preclinical development and has not yet entered clinical trials[1].
- Other names
- MET-067iMET067iMET 067iMET-067MET067MET 067
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on MET-067i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MET-067i.